Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
November 14, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
October 17, 2025 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
October 09, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

GLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
September 16, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
September 03, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 20, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments

GLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 14, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 06, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE)...
July 16, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...